onlinelibrary.wiley.com
Safety and efficacy of adalimumab 40 mg every 3 weeks in pediatric‐onset Crohn's disease
Cure8 flagged this item because the article title and available source metadata connect it to Crohn's disease, Adalimumab, Anti-TNF, and Medications. We do not yet have enough reliable article text to summarize the details.
This may be most useful for Pediatric Patients and Parents Caregivers following Crohn's disease, Adalimumab, Anti-TNF, and Medications.
What To Know
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a clinical study related to Crohn's disease, Adalimumab, Anti-TNF, and Medications. Use the original source link for the full details.
Study details such as design, patient population, comparison group, and measured outcomes matter. The original source has the full context.
